神威藥業(02877.HK)2021年純利勁升88.7%至5.57億元 各劑型均全線增長
格隆匯3月29日丨神威藥業(02877.HK)公佈2021年度業績，期內集團實現營業額32.24億元人民幣(單位下同)，同比增長21.4%；毛利24.10億元，同比增長21.3%；公司擁有人應占年內溢利5.57億元，同比增長88.7%；每股基本盈利為74分，宣派中期股息每股21分。
於2021年，集團聚焦佈局重點產品，全面加強終端覆蓋和投入，滑膜炎顆粒等集團獨家產品於年內增長強勁，注射液產品整體每個季度比去年均錄得可觀的銷售增長，中藥配方顆粒繼續保持上升勢頭，各劑型整體均全線增長。
國家政府多次強調堅持中西醫結合治療，數箇中藥注射液(包括集團有生產的參麥注射液)被列入了《新型冠狀病毒肺炎診療方案(試行第七版)》，突出了中藥注射液的有效性及安全性，集團同時亦積極優化注射液產品組合，令今年整體注射液產品銷售額同比增長21.5%，這已是注射液產品自2013年以來經過多年下滑後銷量五個季度連續走高。主要用於醫院的冠心寧注射液於年內得人民幣2.95億的銷售收入，比去年大幅增加71.2%。而參麥注射液和用於基層醫療機構的清開靈注射液的銷售額分別上升10.7%及18.4%。集團生物製劑產品銅綠假單胞菌注射液亦比去年上升了15.3%。
集團於2021年繼續以拓展口服制劑新增長點為重點發展策略，口服產品2021年整體銷售額同比增長21.3%，於2021年上半年軟膠囊、顆粒劑和中藥配方顆粒產品銷售額較去年同期分別上升7.6%、61.8%及34.1%，口服產品銷售比例已達集團整體銷售額的58.5%。
新冠疫情受控後集團的小兒顆粒劑產品需求顯著回升，重點產品小兒清肺化痰顆粒錄得的銷售額比去年上升38.6%。與此同時，集團獨家產品滑膜炎顆粒已成為集團最大的顆粒產品，年內錄得51.2%的銷售增長，令整體顆粒劑產品銷售額於年內上升了31.4%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
